Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad's myChoice To Be Used In More Cancer Clinical Trials

This article was originally published in The Gray Sheet

Executive Summary

Myriad is continuing its mission to expand its companion diagnostics reach by teaming up with Tesaro and Merck to evaluate their breast and ovarian cancer drugs, and expanding its partnership with Abbvie into lung cancer. .

Advertisement

Related Content

August M&A Analysis: Slow Month Highlighted By Unique Technologies
Myriad To Enter Neuroscience Market With $225m Assurex Acquisition
More Companion Diagnostic Deals For Qiagen And Myriad
Myriad Enters Companion Diagnostics Field With An FDA First

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT035001

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel